330 related articles for article (PubMed ID: 12964023)
21. Epigenetic silencing of maspin gene expression in human breast cancers.
Domann FE; Rice JC; Hendrix MJ; Futscher BW
Int J Cancer; 2000 Mar; 85(6):805-10. PubMed ID: 10709100
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis.
Boltze C; Zack S; Quednow C; Bettge S; Roessner A; Schneider-Stock R
Pathol Res Pract; 2003; 199(6):399-404. PubMed ID: 12924440
[TBL] [Abstract][Full Text] [Related]
23. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells.
Jiang WG; Hiscox S; Horrobin DF; Bryce RP; Mansel RE
Biochem Biophys Res Commun; 1997 Aug; 237(3):639-44. PubMed ID: 9299418
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
25. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
26. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing.
Xing M; Usadel H; Cohen Y; Tokumaru Y; Guo Z; Westra WB; Tong BC; Tallini G; Udelsman R; Califano JA; Ladenson PW; Sidransky D
Cancer Res; 2003 May; 63(9):2316-21. PubMed ID: 12727856
[TBL] [Abstract][Full Text] [Related]
27. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
28. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin.
Zhang M; Maass N; Magit D; Sager R
Cell Growth Differ; 1997 Feb; 8(2):179-86. PubMed ID: 9040939
[TBL] [Abstract][Full Text] [Related]
29. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
30. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
31. IGSF4 promoter methylation and expression silencing in human cervical cancer.
Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
[TBL] [Abstract][Full Text] [Related]
32. RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma.
Lal G; Padmanabha L; Smith BJ; Nicholson RM; Howe JR; O'Dorisio MS; Domann FE
Cancer; 2006 Dec; 107(12):2752-9. PubMed ID: 17103461
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
[TBL] [Abstract][Full Text] [Related]
35. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation.
Yatabe Y; Mitsudomi T; Takahashi T
Oncogene; 2004 May; 23(23):4041-9. PubMed ID: 15048080
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathology of differentiated thyroid cancer.
Greco A; Borrello MG; Miranda C; Degl'Innocenti D; Pierotti MA
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):440-53. PubMed ID: 19910897
[TBL] [Abstract][Full Text] [Related]
37. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.
Overmeer RM; Henken FE; Bierkens M; Wilting SM; Timmerman I; Meijer CJ; Snijders PJ; Steenbergen RD
J Pathol; 2009 Nov; 219(3):327-36. PubMed ID: 19662663
[TBL] [Abstract][Full Text] [Related]
38. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
39. Maspin is up-regulated in premalignant prostate epithelia.
Pierson CR; McGowen R; Grignon D; Sakr W; Dey J; Sheng S
Prostate; 2002 Dec; 53(4):255-62. PubMed ID: 12430137
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation.
Shutoh M; Oue N; Aung PP; Noguchi T; Kuraoka K; Nakayama H; Kawahara K; Yasui W
Cancer; 2005 Oct; 104(8):1609-19. PubMed ID: 16134180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
